IRVING, Texas, Oct. 6, 2021 /PRNewswire/ Caris Life Sciences®, a molecular science company developing and delivering technologies to revolutionize healthcare, announced today the.
To embed, copy and paste the code into your website or blog:
Sixth Street has led an $830 million growth equity investment into Caris Life Sciences, according to a news release.
Caris, based in Irving, Texas, develops molecular profiling assays for oncology that scan DNA, RNA and proteins to reveal a molecular blueprint intended to help physicians and patients make more precise and personalized cancer treatment decisions.
Sixth Street, based in San Francisco, is a global investment firm. Founded in 2009, the firm’s healthcare and life sciences team provides strategic growth capital tailored to healthcare and pharma business timelines including to develop or launch new medicines, make asset acquisitions and fund strategic projects.
IRVING, Texas, May 11, 2021 /PRNewswire/ Caris Life Sciences
®, a leading innovator in molecular science and artificial intelligence (AI) focused on fulfilling the promise of precision medicine, announced an $830 million growth equity round at a post-money valuation of $7.83 billion. With this investment, Caris has raised approximately $1.3 billion in external financing since 2018. This financing represents one of the largest capital raises in precision medicine and includes a diverse syndicate of leading investors.
The round was led by Sixth Street, a leading global investment firm making its third investment in Caris since 2018. Funds and accounts advised by T. Rowe Price Associates, Inc., Silver Lake, Fidelity Management & Research Company LLC, and Coatue were significant participants in the round. Additional investors included Columbia Threadneedle Investments, Canada Pension Plan Investment Board, Millennium Management, Neuberger Berman Funds, Highland Capital Management,
Caris Life Sciences Raises $830M in Growth Equity Funding
Caris Life Sciences, an Irving, Texas-based innovator in molecular science and artificial intelligence (AI) focused on fulfilling the promise of precision medicine, raised $830m in growth equity funding at a post-money valuation of $7.83 billion.
The round was led by Sixth Street, with participation from funds and accounts advised by T. Rowe Price Associates, Inc., Silver Lake, Fidelity Management & Research Company LLC, Coatue, Columbia Threadneedle Investments, Canada Pension Plan Investment Board, Millennium Management, Neuberger Berman Funds, Highland Capital Management, Rock Springs Capital, OrbiMed, ClearBridge Investments, Tudor Investment Corporation, Eaton Vance Equity (Morgan Stanley), Pura Vida Investments and First Light Asset Management.
Share:
Accelerates revenue growth through
Facilitates future global expansion via EOS established infrastructure
Leverages the portfolio adoption driven by SafeOp with significant
incremental opportunities to monetize clinical information
Hosting webcast for investors December 17 at 6:00 A.M. PT
CARLSBAD, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) Alphatec Holdings, Inc. ( ATEC or the Company ) (NASDAQ:ATEC), a medical device company dedicated to revolutionizing the approach to spine surgery, announced today that it has entered into an agreement to acquire EOS imaging, SA, for a purchase price of $79.7 million, plus the retirement debt of $37.2 million, in an all-cash transaction. SafeOp has substantiated the value of clinically actionable information by accelerating product adoption across our portfolio, said Pat Miles, Chairman and Chief Executive Officer. Our original investment thesis for EOS as a solution to better inform surgery never changed. With this transactio